Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Ketamine Taskforce Addresses the Passing of Matthew Perry, Advocating for Safe Ketamine Use in an Appropriate Clinical Context

Boca Raton, Florida (Newsworthy.ai) Thursday Dec 21, 2023 @ 6:00 AM Pacific —

The Ketamine Taskforce mourns the passing of Matthew Perry, a tragedy that has been partially attributed to the use of ketamine outside of an appropriate clinical context. This incident underscores the urgent need for public education on ketamine's role in mental health when used in a medically appropriate setting.

Ketamine, an essential medicine listed by the World Health Organization’s list of top 10 most crucial drugs, has a long history as an effective and well-tolerated anesthetic. It’s used for pediatric anesthesia around the world, on the battlefield by medics and on ambulances. Its emerging role over the past two decades in treating mental health conditions, particularly those resistant to conventional therapies, is supported by extensive research.

We have a mental health and suicide crisis in this country that is not being met by mainstream medications and therapy. Ketamine works better and faster than most traditional antidepressants. Research shows that it can stop suicidal ideation within 1 to 6 doses, with 63% of study participants experiencing resolution of suicidal ideation in 3 days compared with 31.6% in the group that received placebo. Traditional antidepressants can take 6-8 weeks to have a significant effect and even then research suggests they may only be effective in around 1/3rd of patients.

Compared to opioids, ketamine's potential for abuse is considerably lower. Nearly 107,000 deaths from opiate drug overdoses from occurred between 2021 and 2022. Fentanyl caused 74,000 known deaths in the US in 2022. Per the CDC Ketamine caused about 30, usually in combination with other drugs. However, its safety and efficacy are contingent on the safe use under the guidance of trained medical and mental health professionals.

The Ketamine TaskForce is committed to advocating for the safe, clinical use of ketamine, ensuring its role as a beneficial tool in treating mental health and pain conditions. We believe ketamine addresses a crucial gap in mental health care, providing a viable, fast-acting approach to those in dire need. As we confront this tragic loss, we are reminded of the importance of medical supervision and the potential of ketamine, when used correctly, to save lives and alleviate suffering.

About the Ketamine TaskForce:

The Ketamine Task Force is a dedicated non-profit organization, operated entirely by volunteers. Our mission is to promote the responsible use of ketamine in clinical settings, emphasizing its potential in treating various mental health and pain conditions. We focus on enhancing safe care, accessibility, and education regarding ketamine therapy, while also advocating for improved insurance coverage. Serving a diverse group including veterans, first responders, and health professionals, we are committed to raising awareness about the benefits and risks associated with ketamine treatment, ensuring that it remains an accessible and responsibly used option in mental health care.

For further information or to contribute to our cause, please visit https://www.ketaminetaskforce.org/


This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform.™

The reference URL for this press release is located here Ketamine Taskforce Addresses the Passing of Matthew Perry, Advocating for Safe Ketamine Use in an Appropriate Clinical Context.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.